Young Tak Lim

Prof. Dr. Young Tak Lim


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2007 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
HPHyun Seok Park
Hyun Seok Park
MSMin Jung Sung
Min Jung Sung
SPSu Eun Park
Su Eun Park
YLYoung Tak Lim
Young Tak Lim

23 May 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
THThe Hereditary Hemolytic Anemia Working Party Of The Korean Society Of Hematology
The Hereditary Hemolytic Anemia Working Party Of The Korean Society Of Hematology
HCHyoung Soo Choi
Hyoung Soo Choi
QCQute Choi
Qute Choi
JKJung-Ah Kim
Jung-Ah Kim
KIKyong Ok Im
Kyong Ok Im
DLDong-Soon Lee
Dong-Soon Lee
Current diagnostic tests for hereditary spherocytosis (HS) focus on the detection of hemolysis or indirectly assessing defects of membrane protein, whereas direct methods to detect protein defects are complicated and difficult to implement. In the present study, we investigated the patterns of genetic variation associated with HS among patients clinically diagnosed with HS. Multi-gene targeted sequencing of 43 genes (17 RBC membrane protein-encoding genes, 20 RBC enzyme-encoding genes, and six additional genes for the differential diagnosis) was performed using the Illumina HiSeq platform. Among 59 patients with HS, 50 (84.7%) had one or more significant variants in a RBC membrane protein-encoding genes. A total of 54 significant variants including 46 novel mutations were detected in six RBC membrane protein-encoding genes, with the highest number of variants found in SPTB (n = 28), and followed by ANK1 (n = 19), SLC4A1 (n = 3), SPTA1 (n = 2), EPB41 (n = 1), and EPB42 (n = 1). Concurrent mutations of genes encoding RBC enzymes (ALDOB, GAPDH, and GSR) were detected in three patients. UGT1A1 mutations were present in 24 patients (40.7%). Positive rate of osmotic fragility test was 86.8% among patients harboring HS-related gene mutations. This constitutes the first large-scaled genetic study of Korean patients with HS. We demonstrated that multi-gene target sequencing is sensitive and feasible that can be used as a powerful tool for diagnosing HS. Considering the discrepancies of clinical and molecular diagnoses of HS, our findings suggest that molecular genetic analysis is required for accurate diagnosis of HS.

1 January 2014 in Blood Research
Verified
Journal Article
Open access
PDF file
SKSeom Gim Kong
Seom Gim Kong
JSJung Ho Seo
Jung Ho Seo
SJSo Eun Jun
So Eun Jun
BLByung Ki Lee
Byung Ki Lee
YLYoung Tak Lim
Young Tak Lim
Kong SG, et al. Blood Res. 2014 Mar;49(1):29-35. http://dx.doi.org/10.5045/br.2014.49.1.29

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YSYe Jee Shim
Ye Jee Shim
HJHye Lim Jung
Hye Lim Jung
HSHee Young Shin
Hee Young Shin
HKHyoung Jin Kang
Hyoung Jin Kang
JCJung Yoon Choi
Jung Yoon Choi
THThe Red Blood Cell Disorder Working Party Of The Korean Society Of Hematology
The Red Blood Cell Disorder Working Party Of The Korean Society Of Hematology
Shim YJ, et al. J Korean Med Sci. 2020 Jul;35(33):e279. https://doi.org/10.3346/jkms.2020.35.e279

3 March 2020 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
KPKyung Mi Park
Kyung Mi Park
EYEu Jeen Yang
Eu Jeen Yang
JLJae Min Lee
Jae Min Lee
JHJeong Ok Hah
Jeong Ok Hah
SPSang Kyu Park
Sang Kyu Park
YLYoung Tak Lim
Young Tak Lim
Acute lymphoblastic leukemia (ALL) with hyperleukocytosis at diagnosis is associated with early morbidity and mortality due to complications of leukostasis. Of 535 pediatric ALL patients (January 2004 to December 2016 from the Yeungnam region of Korea), 72 (13.5%) patients with an initial white blood cell (WBC) count of ≥100×109/L were included in this study, of whom 38 patients had extreme hyperleukocytosis (WBC>200×109/L) at diagnosis. Fourteen patients (19.4%) had ≥1 early respiratory and neurologic complications during induction therapy. Relapse occurred in 8 patients (24.2%) with extreme hyperleukocytosis and in 1 patient (3.0%) with an initial WBC count of 100 to 200×109/L (P=0.012). Estimated 10-year event-free survival rate (EFS) and overall survival rate were 78.3%±8.4% and 82.6%±7.7%, respectively. The 10-year EFS was significantly lower in patients with an initial WBC count of >200×109/L than in those with an initial WBC count of 100 to 200×109/L (65.7%±13.4% vs. 91.2%±7.9%; P=0.011). The 10-year EFS and overall survival rate did not differ significantly between patients with extreme hyperleukocytosis who received hematopoietic stem cell transplantation and those who received chemotherapy. In conclusion, pediatric ALL with hyperleukocytosis can lead to early complications and mortality. Patients with initial extreme hyperleukocytosis showed significantly poorer prognosis than those with WBC counts of 100 to 200×109/L.

15 January 2022 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
KPKyung Mi Park
Kyung Mi Park
KYKeon Hee Yoo
Keon Hee Yoo
SKSeong Koo Kim
Seong Koo Kim
JLJae Wook Lee
Jae Wook Lee
NCNack-Gyun Chung
Nack-Gyun Chung
YLYoung Tak Lim
Young Tak Lim
Purpose Acute promyelocytic leukemia (APL) is a rare disease in children and there are some different characteristics between children and adult. We aimed to evaluate incidence, clinical characteristics and treatment outcomes of pediatric APL in Korea.Materials and Methods Seventy-nine pediatric APL patients diagnosed from January 2009 to December 2016 in 16 tertiary medical centers in Korea were reviewed retrospectively.Results Of 801 acute myeloid leukemia children, 79 (9.9%) were diagnosed with APL. The median age at diagnosis was 10.6 years (range, 1.3 to 18.0). Male and female ratio was 1:0.93. Thirty patients (38.0%) had white blood cell (WBC) count greater than 10×109/L at diagnosis. All patients received induction therapy consisting of all-trans retinoic acid and chemotherapy. Five patients (6.6%) died during induction chemotherapy and 66 patients (86.8%) achieved complete remission (CR) after induction chemotherapy. The causes of death were three intracranial hemorrhage, one cerebral infarction, and one sepsis. Five patients (7.1%) suffered a relapse during or after maintenance chemotherapy. The estimated 4-year event-free survival and overall survival (OS) rates were 82.1%±4.4%, 89.7%±5.1%, respectively. The 4-year OS was significantly higher in patients with initial WBC < 10×109/L than in those with initial WBC ≥ 10×109/L (p=0.020).Conclusion This study showed that the CR rates and survival outcomes in Korean pediatric APL patients were relatively good. The initial WBC count was the most important prognostic factor and most causes of death were related to serious bleeding in the early stage of treatment.